Skip to content

Serum fibrinogen and fibrin degradation products (FDP) changes in hypothermia and normothermia in patients undergoing bypass

Assessing serum fibrinogen and fibrin degradation products (FDP) changes in hypothermia and normothermia in patients undergoing cardiopulmonary bypass

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180930041189N1
Enrollment
80
Registered
2019-02-10
Start date
2018-05-22
Completion date
Unknown
Last updated
2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease. Atherosclerotic heart disease of native coronary artery

Interventions

Intervention 1: Intervention group: hyporthermic group: In this group, the temperature of the body was reduced untile 30- 34.9 ° C by a heater-cooler and a blanket (temperature changer). Intervention

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 85 Years

Inclusion criteria

Inclusion criteria: All adult patients undergoing heart surgery Patients between 25 and 85 years

Exclusion criteria

Exclusion criteria: History of thrombosis bleeding regular aspirin use in the past 5 days congenital fibrinogen disorders liver disease disorders or coagulation deficiencies genetic disorders such as hemophilia chronic renal failure patients people with substance abuse

Design outcomes

Primary

MeasureTime frame
The amount of fibrinogen consumed and the production of fibrinogen degradation products. Timepoint: At the beginning of the study (before the intervention) and during the bypass in two intervals after the intervention. Method of measurement: Fibrinogen using the clauss and FDP method with serology (kit ELISA).

Secondary

MeasureTime frame
Postoperative bleeding. Timepoint: 24 hours after entering ICU. Method of measurement: Measuring Chest tube bleeding.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBahram Ghasemzadeh

Shiraz University of Medical Sciences

m.ghodrati87@gmail.com+98 71 3230 5410

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026